Page 148 - 2020_09-Haematologica-web

M. Seibold et al.
Ral overactivation in malignant peripheral
nerve sheath tumors. Mol Cell Biol. 2009;
29(14):3964-3974.
55. De Gorter DJJ, Reijmers RM, Beuling EA, et
al. The small GTPase Ral mediates SDF-1 - induced migration of B cells and multiple myeloma cells. Blood. 2008;111(7):3364- 3372.
56. Wilson CY, Tolias P. Recent advances in cancer drug discovery targeting RAS. Drug Discov Today. 2016;21(12):1915-1919.
57. Skorobogatko Y, Dragan M, Cordon C, et al. RalA controls glucose homeostasis by
regulating glucose uptake in brown fat. Proc Natl Acad Sci. 2018;115(30):7819- 7824.
58. Gu C, Feng M, Yin Z, Luo X, Yang J. RalA, a GTPase targeted by miR 181a, promotes transformation and progression by activat- ing the Ras related signaling pathway in chronic myelogenous leukemia. Oncotarget. 2016;7(15):20561-20573.
59. Schinke C, Qu P, Mehdi SJ, et al. The pat- tern of mesenchymal stem cell expression is an independent marker of outcome in multiple myeloma. Clin Cancer Res. 2018;
24(12):2913-2919.
60. Garayoa M, Garcia JL, Santamaria C, et al.
Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from nor- mal donors. Leukemia. 2009;23(8):1515- 1527.
61. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125(20):3049-3058.
62. Markman B, J. Tao J, Scaltriti M. PI3K path- way inhibitors: better not left alone. Curr Pharm Des. 2013;19(5):895-906.
2326
haematologica | 2020; 105(9)